佐藤 博亮 さとう ひろあき 先生

来歴等

略歴

1992年 秋田大学医学部 卒業
1992年 東京大学医学部附属病院 内科 研修医
1993年 東京都立墨東病院 救命救急センター 非常近医
1993年 さいたま赤十字病院 内科 研修医
1994年 さいたま赤十字病院 内科 常勤医
1995年 東京大学医学部附属病院 第一内科 医員
1996年 東京大学大学院 医学系研究科 内科学専攻 入進
2000年 東京大学大学院 医学研究系研究科 内科学専攻 卒業
2000年 東京大学医学部附属病院 文部科学教官 助手
2001年 カリフォルニア大学サンディエゴ校 代謝内分泌内科 研究員
2004年 福島県立医科大学 内科学第三講座 講師
2010年 福島県立医科大学 腎臓高血圧・糖尿病内分泌代謝内科 准教授
2016年 順天堂大学 医学部 代謝内分泌内科学講座 先任准教授
2021年 順天堂大学医学部附属浦安病院 糖尿病・内分泌内科 先任准教授
2023年 順天堂大学大学院 医学研究科 代謝異分泌医科学 教授
2023年 順天堂大学医学部附属浦安病院 糖尿病・内分泌内科 教授
2026年 順天堂大学医学部附属浦安病院 院長補佐

もっと見る

論文

• 1. Efficacy of probiotics (Bifidobacterium bifidum G9-1) in patients with type 2 diabetes mellitus and chronic kidney disease complicated by constipation: An exploratory, multicenter, open-label, single-arm study (BIRDIE study). J Diabetes Investig. 2026;17(3):470-482.

  Ikeda, J. Sato, H. Yoshii, M. Sugawara, H. Satoh, Y. Sugawara, H. Uzawa, D. Sugimoto, R. Muto, Y. Nishida, and H. Watada.

• 2. Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open-label clinical trial (RESOLUTION study). J Diabetes Investig. 2025;16(12):2160-2172.

  M. Kitada, M. Toyoda, O. Sekine, D. Suzuki, Y. Okada, Y. Morita, H. Nishimura, H. Satoh, H. Kamiya, T. Takamura, M. Isono, T. Onoue, H. Arima, K. Tanaka, M. Miyamoto, Y. Omura, D. Yabe, T. Kato, A. Asano, Y. Wakasa, S. Miyamoto, S. Kume, T. Ito, S. I. Araki, A. Nakagawa, and Resolution Study Investigators.

• 3. A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes-2nd Edition (English version). Diabetol Int. 2024;15(3):327-345.

  R. Bouchi, T. Kondo, Y. Ohta, A. Goto, D. Tanaka, H. Satoh, D. Yabe, R. Nishimura, N. Harada, H. Kamiya, R. Suzuki, T. Yamauchi, and J. D. S. Committee on Consensus Statement Development.

• 4. A 7 day inpatient diabetes education program improves quality of life and glycemic control 12 months after discharge. J Diabetes Investig. 2023;14(6):811-820.

  M. Kurita, H. Satoh, H. Kaga, S. Kadowaki, Y. Someya, Y. Tosaka, Y. Nishida, F. Ikeda, Y. Tamura, and H. Watada.

• 5. A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes. Diabetol Int. 2023;14(1):1-14.

  R. Bouchi, T. Kondo, Y. Ohta, A. Goto, D. Tanaka, H. Satoh, D. Yabe, R. Nishimura, N. Harada, H. Kamiya, R. Suzuki, and T. Yamauchi.

• 6. Relationship Between Risk of Hyper-Low-density Lipoprotein Cholesterolemia and Evacuation After the Great East Japan Earthquake. J Epidemiol. 2022;32(6):277-282.

  H. Satoh, K. Okazaki, T. Ohira, A. Sakai, M. Hosoya, S. Yasumura, Y. Kawasaki, K. Hashimoto, A. Ohtsuru, A. Takahashi, K. Watanabe, M. Shimabukuro, J. J. Kazama, S. Hashimoto, G. Kobashi, H. Ohira, H. Ohto, and K. Kamiya.

• 7. Influence of Short-Term Dietary and Therapeutic Iodine Restriction on the Therapeutic Effects of Radioactive Iodine Therapy in Patients with Graves' Disease. Thyroid. 2021;31(3):439-445.

  R. Nishio, T. Uchida, L. Suzuki, H. Onose, H. Goto, E. Yamada, H. Satoh, and H. Watada.

• 8. Adipose Insulin Resistance and Decreased Adiponectin Are Correlated With Metabolic Abnormalities in Nonobese Men. J Clin Endocrinol Metab. 2021;106(5):e2228-e2238.

  M. Kiya, Y. Tamura, K. Takeno, Y. Someya, S. Kakehi, M. Sato, N. Yamasaki, S. Kadowaki, R. Suzuki, Y. Furukawa, D. Sugimoto, H. Kaga, T. Funayama, M. Nishitani-Yokoyama, K. Shimada, H. Daida, S. Aoki, H. Satoh, R. Kawamori, and H. Watada.

• 9. Plasma glucagon levels measured by sandwich ELISA are correlated with impaired glucose tolerance in type 2 diabetes. Endocr J. 2020;67(9):903-922.

  M. Kobayashi, H. Satoh, T. Matsuo, Y. Kusunoki, M. Tokushima, H. Watada, M. Namba, and T. Kitamura.

• 10. Evacuation is a risk factor for diabetes development among evacuees of the Great East Japan earthquake: A 4-year follow-up of the Fukushima Health Management Survey. Diabetes Metab. 2019;45(3):312-315.

  H. Satoh, T. Ohira, M. Nagai, M. Hosoya, A. Sakai, S. Yasumura, A. Ohtsuru, Y. Kawasaki, H. Suzuki, A. Takahashi, Y. Sugiura, H. Shishido, Y. Hayashi, H. Takahashi, G. Kobashi, K. Ozasa, S. Hashimoto, H. Ohto, M. Abe, K. Kamiya, and Group Fukushima Health Management Survey.

• 11. Liver-specific G0 /G1 switch gene 2 (G0s2) expression promotes hepatic insulin resistance by exacerbating hepatic steatosis in male Wistar rats, J Diabetes. 2017;9(8):754-763.

  Y. Sugaya and H. Satoh.

• 12. Effects of linagliptin vs. voglibose on daily glucose excursions during continuous glucose monitoring of Japanese type 2 diabetes patients (L-CGM): A randomized, open-label, two-arm, parallel comparative trial. Diabetes Metab. 2017;43(6):550-553.

  H. Satoh, T. Ohira, C. Moriya, I. Inoue, S. Kuribayashi, H. Seino, H. Hirai, T. Hiyoshi, H. Watada, and L. Cgm Study Group.

• 13. Prevalence of Renal Dysfunction among Evacuees and Non-evacuees after the Great East Earthquake: Results from the Fukushima Health Management Survey. Intern Med. 2016;55(18):2563-2569.

  H. Satoh, T. Ohira, M. Nagai, M. Hosoya, A. Sakai, T. Watanabe, A. Ohtsuru, Y. Kawasaki, H. Suzuki, A. Takahashi, G. Kobashi, K. Ozasa, S. Yasumura, S. Yamashita, K. Kamiya, and M. Abe.

• 14. Hypo-high-density Lipoprotein Cholesterolemia Caused by Evacuation after the Fukushima Daiichi Nuclear Power Plant Accident: Results from the Fukushima Health Management Survey. Intern Med. 2016;55(15):1967-1976.

  H. Satoh, T. Ohira, M. Nagai, M. Hosoya, A. Sakai, T. Watanabe, A. Ohtsuru, Y. Kawasaki, H. Suzuki, A. Takahashi, G. Kobashi, K. Ozasa, S. Yasumura, S. Yamashita, K. Kamiya, and M. Abe.

• 15. Teneligliptin Decreases Uric Acid Levels by Reducing Xanthine Dehydrogenase Expression in White Adipose Tissue of Male Wistar Rats. J Diabetes Res. 2016;2016:3201534.

  C. Moriya and H. Satoh.

• 16. Evacuation after the Fukushima Daiichi Nuclear Power Plant Accident Is a Cause of Diabetes: Results from the Fukushima Health Management Survey. J Diabetes Res. 2015;2015:627390.

  H. Satoh, T. Ohira, M. Hosoya, A. Sakai, T. Watanabe, A. Ohtsuru, Y. Kawasaki, H. Suzuki, A. Takahashi, G. Kobashi, K. Ozasa, S. Yasumura, S. Yamashita, K. Kamiya, and M. Abe.

• 17. Yacon supplementation reduces serum free fatty acids and tumor necrosis factor alpha concentrations in patients with type 2 diabetes. Diabetol Int. 2014;5(3):165-174.

  H. Satoh, A. Kudoh, K. Hasegawa, H. Hirai, and T. Watanabe.

• 18. Pitavastatin Ameliorates Insulin Resistance in Type 2 Diabetic Patients: Report of Two Cases. J Diabetes Metab. 2013;4(1):237.

  H. Satoh, A. Kudoh, H. Hirai, and T. Watanabe.

• 19. Yacon diet (Smallanthus sonchifolius, Asteraceae) improves hepatic insulin resistance via reducing Trb3 expression in Zucker fa/fa rats. Nutr Diabetes 3. 2013;e70.

  H. Satoh, M. T. Audrey Nguyen, A. Kudoh, and T. Watanabe.

• 20. Interaction between resistin and adiponectin in the proliferation of rat vascular smooth muscle cells. Mol Cell Endocrinol. 2013;366(1):108-116.

  H. Hirai, H. Satoh, A. Kudoh, and T. Watanabe.

• 21. Adiponectin reduces proteinuria in streptozotocin-induced diabetic Wistar rats. Exp Biol Med (Maywood). 2011;236(5):614-620.

  S. Nakamaki, H. Satoh, A. Kudoh, Y. Hayashi, H. Hirai, and T. Watanabe.

• 22. Pioglitazone upregulates adiponectin receptor 2 in 3T3-L1 adipocytes. Life Sci. 2011;88(23-24):1055-1062.

  A. Kudoh, H. Satoh, H. Hirai, and T. Watanabe.

• 23. Adenovirus-mediated adiponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats. Diabetes. 2005;54(5):1304-1313.

  H. Satoh, M. T. A. Nguyen, M. Trujillo, T. Imamura, I. Usui, P. E. Scherer, and J. M. Olefsky.

• 24. Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats. J Clin Invest. 2004;114(2):224-231.

  H. Satoh, M. T. Nguyen, P. D. Miles, T. Imamura, I. Usui, and J. M. Olefsky.

• 25. PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat Med. 2004;10(5):530-534.

  S. H. Koo, H. Satoh, S. Herzig, C. H. Lee, S. Hedrick, R. Kulkarni, R. M. Evans, J. Olefsky, and M. Montminy.

• 26. Localization of Na+-HCO-3 cotransporter (NBC-1) variants in rat and human pancreas. Am J Physiol Cell Physiol. 2003;284(3):C729-737.

  H. Satoh, N. Moriyama, C. Hara, H. Yamada, S. Horita, M. Kunimi, K. Tsukamoto, O. N. Iso, J. Inatomi, H. Kawakami, A. Kudo, H. Endou, T. Igarashi, A. Goto, T. Fujita, and G. Seki.

• 27. Molecular basis of ocular abnormalities associated with proximal renal tubular acidosis. J Clin Invest. 2001;108(1):107-115.

  T. Usui, M. Hara, H. Satoh, N. Moriyama, H. Kagaya, S. Amano, T. Oshika, Y. Ishii, N. Ibaraki, C. Hara, M. Kunimi, E. Noiri, K. Tsukamoto, J. Inatomi, H. Kawakami, H. Endou, T. Igarashi, A. Goto, T. Fujita, M. Araie, and G. Seki.

• 28. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function. Biochem Biophys Res Commun. 1999;254(3):757-763.

  H. Satoh, K. Tsukamoto, Y. Hashimoto, N. Hashimoto, M. Togo, M. Hara, H. Maekawa, N. Isoo, S. Kimura, and T. Watanabe.

• 29. Mutations in SLC4A4 cause permanent isolated proximal renal tubular acidosis with ocular abnormalities. Nat Genet. 1999;23(3):264-266.

  T. Igarashi, J. Inatomi, T. Sekine, S. H. Cha, Y. Kanai, M. Kunimi, K. Tsukamoto, H. Satoh, M. Shimadzu, F. Tozawa, T. Mori, M. Shiobara, G. Seki, and H. Endou.

• 30. Advanced glycation endproducts stimulate mitogen-activated protein kinase and proliferation in rabbit vascular smooth muscle cells. Biochem Biophys Res Commun. 1997;239(1):111-115.

  H. Satoh, M. Togo, M. Hara, T. Miyata, K. Han, H. Maekawa, M. Ohno, Y. Hashimoto, K. Kurokawa, and T. Watanabe.

もっと見る